Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
November 23, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual...
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 01, 2022 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q3 2022 net revenue of $33.4 million –– RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
October 31, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022,...
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
September 12, 2022 08:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
August 03, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow...
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 03, 2022 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront and near-term proceeds of $100 million...
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
August 03, 2022 07:29 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as royalties on net sales – – Global license...
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
August 02, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022,...
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 03, 2022 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash reserves expected to fund operations into at...
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
May 02, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30...